Background: Perinatal hypoxic-ischemic brain damage is a major cause of acute mortality and chronic neurological morbidity in infants and children. Oxidative stress due to free radical formation and the initiation of abnormal oxidative reactions appears to play a key role. Docosahexanoic acid (DHA), a main component of brain membrane phospholipids, may act as a neuroprotectant after hypoxia-ischemia by regulating multiple molecular pathways and gene expression. Objectives: The aims of this study were to test the hypothesis that DHA provides significant protection against lipoperoxidation damage in the cerebral cortex and hippocampus in a neonatal piglet model of severe hypoxia-reoxygenation. Methods: Newborn piglets, Noroc (LYLD), were subjected to severe global hypoxia. One group was resuscitated with ambient air (21% group, n = 11) and another also received 5 mg/kg of DHA 4 h after the end of hypoxia (21% DHA group, n = 10). After 9.5 h, tissues from the prefrontal cortex and hippocampus were sampled and the levels of isoprostanes, neuroprostanes, neurofurans, and F2-dihomo-isoprostanes were determined by the liquid chromatography triple quadrupole mass spectrometry technique. Results: Lipid peroxidation biomarkers were significantly lower in both the cortex and hippocampus in the DHA-treated group compared with the untreated group. Conclusions: The present study demonstrates that DHA administration after severe hypoxia in newborn piglets has an antioxidative effect in the brain, suggesting a protective potential of DHA if given after injuries to the brain.

Keywords:
Oxidative stress, Brain injury, Docosahexanoic acid, Newborn infant, Lipid metabolism
1.
Bryce J, Boschi-Pinto C, Shibuya K, Black RE: WHO estimates of the causes of death in children. Lancet 2005;365:1147-1152.
2.
Gunn AJ, Bennet L: Fetal hypoxia insults and patterns of brain injury: insights from animal models. Clin Perinatol 2009;36:579-593.
3.
Arneson KO, Roberts LJ: Measurement of products of docosahexaenoic acid peroxidation, neuroprostanes, and neurofurans. Methods Enzymol 2007;433:127-143.
4.
Sastry PS: Lipids of nervous tissue: composition and metabolism. Prog Lipid Res 1985;24:69-176.
5.
VanRollins M, Woltjer RL, Yin H, Morrow JD, Montine TJ: F2-dihomo-isoprostanes arise from free radical attack on adrenic acid. J Lipid Res 2008;49:995-1005.
6.
Belik J, Gonzalez-Luis GE, Perez-Vizcaino F, Villamor E: Isoprostanes in fetal and neonatal health and disease. Free Radic Biol Med 2010;48:177-188.
7.
Chen Y, Morrow JD, Roberts LJ: Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J Biol Chem 1999;274:10863-10868.
8.
Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ: A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-9387.
9.
Roberts LJ, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD: Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998;273:13605-13612.
10.
Solberg R, Longini M, Proietti F, Vezzosi P, Saugstad OD, Buonocore G: Resuscitation with supplementary oxygen induces oxidative injury in the cerebral cortex. Free Radical Biol Med 2012;53:1061-1067.
11.
Luchtman DW, Song C: Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology 2013;64:550-565.
12.
Rogers LK, Valentine CJ, Keim SA: DHA supplementation: current implications in pregnancy and childhood. Pharmacol Res 2013;70:13-19.
13.
Berman DR, Liu Y, Barks J, Mozurkewich E: Treatment with docosahexaenoic acid after hypoxia-ischemia improves forepaw placing in a rat model of perinatal hypoxia-ischemia. Am J Obstet Gynecol 2010;203:385.e1-e5.
14.
Berman DR, Mozurkewich E, Liu Y, Shangguan Y, Barks JD, Silverstein FS: Docosahexaenoic acid augments hypothermic neuroprotection in a neonatal rat asphyxia model. Neonatology 2013;104:71-78.
15.
Rapoport SI, Chang MC, Spector AA: Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res 2001;42:678-685.
16.
Leung KS, Galano JM, Durand T, Lee JC: Current development in non-enzymatic lipid peroxidation products, isoprostanoids and isofuranoids, in novel biological samples. Free Radic Res 2015;49:816-826.
17.
Back SA, Luo NL, Mallinson RA, O'Malley JP, Wallen LD, Frei B, Morrow JD, Petito CK, Roberts CT Jr, Murdoch GH, Montine TJ: Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol 2005;58:108-120.
18.
Hou X, Roberts LJ, Gobeil F Jr, Taber D, Kanai K, Abran D, Brault S, Checchin D, Sennlaub F, Lachapelle P, Varma D, Chemtob S: Isomer-specific contractile effects of a series of synthetic F2-isoprostanes on retinal and cerebral microvasculature. Free Radic Biol Med 2004;36:163-172.
19.
VanRollins M, Woltjer RL, Yin H, Morrow JD, Montine TJ: F2-dihomo-isoprostanes arise from free radical attack on adrenic acid. J Lipid Res 2008;49:995-1005.
20.
Volpe JJ: Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol 2009;8:110-124.
21.
Dobbing J, Sands J: Comparative aspects of the brain growth spurt. Early Hum Dev 1979;3:79-83.
22.
Asikainen TM, White CW: Antioxidant defenses in the preterm lung: role for hypoxia-inducible factors in BPD? Toxicol Appl Pharmacol 2005;203:177-188.
23.
Volpe JJ, Kinney HC, Jensen FE, Rosenberg PA: The developing oligodendrocyte: key cellular target in brain injury in the premature infant. Int J Dev Neurosci 2011;29:423-440.
24.
Belayev L, Khoutorova L, Atkins KD, Eady TN, Hong S, Lu Y, Obenaus A, Bazan NG: Docosahexaenoic acid therapy of experimental ischemic stroke. Transl Stroke Res 2011;2:33-41.
25.
Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, Fujii Y, Ishibashi Y, Oka J, Shido O: Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 2002;81:1084-1091.
26.
Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr, Frautschy SA, Cole GM: A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005;25:3032-3040.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.